| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | extracellular matrix constituent, lubricant activity | 2.84e-05 | 4 | 44 | 2 | GO:0030197 | |
| GeneOntologyMolecularFunction | modification-dependent protein binding | 8.72e-05 | 206 | 44 | 5 | GO:0140030 | |
| GeneOntologyMolecularFunction | phosphorylation-dependent protein binding | 2.11e-04 | 10 | 44 | 2 | GO:0140031 | |
| GeneOntologyCellularComponent | Golgi lumen | 3.25e-06 | 109 | 44 | 5 | GO:0005796 | |
| Domain | SEA | 1.70e-05 | 22 | 43 | 3 | PF01390 | |
| Domain | SEA | 1.95e-05 | 23 | 43 | 3 | PS50024 | |
| Domain | SEA_dom | 1.95e-05 | 23 | 43 | 3 | IPR000082 | |
| Domain | ZU5 | 1.84e-04 | 9 | 43 | 2 | SM00218 | |
| Domain | ZU5 | 2.30e-04 | 10 | 43 | 2 | PS51145 | |
| Domain | ZU5_dom | 3.37e-04 | 12 | 43 | 2 | IPR000906 | |
| Domain | ZU5 | 3.37e-04 | 12 | 43 | 2 | PF00791 | |
| Domain | SEA | 4.63e-04 | 14 | 43 | 2 | SM00200 | |
| Domain | - | 5.33e-04 | 15 | 43 | 2 | 3.30.70.960 | |
| Domain | DEATH | 1.75e-03 | 27 | 43 | 2 | SM00005 | |
| Domain | Death | 2.61e-03 | 33 | 43 | 2 | PF00531 | |
| Domain | ANK_REPEAT | 2.68e-03 | 253 | 43 | 4 | PS50088 | |
| Domain | ANK_REP_REGION | 2.72e-03 | 254 | 43 | 4 | PS50297 | |
| Domain | Death_domain | 3.45e-03 | 38 | 43 | 2 | IPR000488 | |
| Domain | DEATH_DOMAIN | 3.45e-03 | 38 | 43 | 2 | PS50017 | |
| Domain | UBA-like | 9.54e-03 | 64 | 43 | 2 | IPR009060 | |
| Pathway | REACTOME_DEFECTIVE_GALNT3_CAUSES_HFTC | 2.57e-10 | 16 | 34 | 5 | M27410 | |
| Pathway | REACTOME_DEFECTIVE_C1GALT1C1_CAUSES_TNPS | 3.64e-10 | 17 | 34 | 5 | M27412 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 1.96e-09 | 23 | 34 | 5 | M556 | |
| Pathway | REACTOME_DECTIN_2_FAMILY | 3.81e-09 | 26 | 34 | 5 | M27483 | |
| Pathway | REACTOME_DISEASES_ASSOCIATED_WITH_O_GLYCOSYLATION_OF_PROTEINS | 1.22e-08 | 68 | 34 | 6 | M27303 | |
| Pathway | REACTOME_TERMINATION_OF_O_GLYCAN_BIOSYNTHESIS | 1.64e-07 | 21 | 34 | 4 | MM15706 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION | 2.34e-07 | 111 | 34 | 6 | M27416 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS | 3.52e-07 | 62 | 34 | 5 | M546 | |
| Pathway | REACTOME_DISEASES_OF_GLYCOSYLATION | 1.04e-06 | 143 | 34 | 6 | M27275 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION | 5.87e-06 | 109 | 34 | 5 | MM15164 | |
| Pathway | REACTOME_O_LINKED_GLYCOSYLATION_OF_MUCINS | 1.25e-05 | 60 | 34 | 4 | MM15636 | |
| Pathway | REACTOME_C_TYPE_LECTIN_RECEPTORS_CLRS | 1.98e-05 | 140 | 34 | 5 | M27484 | |
| Pathway | REACTOME_DISEASES_OF_METABOLISM | 2.60e-05 | 250 | 34 | 6 | M27554 | |
| Pathway | REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION | ADAMTS12 MUC16 MUC12 DMP1 ANK2 ANK3 INCENP MUC17 MUC4 MUC20 RAD23A OTUD7A | 1.00e-04 | 1475 | 34 | 12 | M19806 |
| Pathway | WP_KCNQ2RELATED_EPILEPSIES | 9.41e-04 | 19 | 34 | 2 | M48320 | |
| Pathway | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER | 1.77e-03 | 26 | 34 | 2 | MM15458 | |
| Pathway | REACTOME_RNA_POLYMERASE_III_TRANSCRIPTION_INITIATION_FROM_TYPE_3_PROMOTER | 2.05e-03 | 28 | 34 | 2 | M1022 | |
| Pathway | REACTOME_INTERACTION_BETWEEN_L1_AND_ANKYRINS | 2.51e-03 | 31 | 34 | 2 | M877 | |
| Pubmed | Mucin gene expression in human laryngeal epithelia: effect of laryngopharyngeal reflux. | 2.17e-11 | 18 | 44 | 5 | 18834073 | |
| Pubmed | 1.89e-09 | 3 | 44 | 3 | 30236127 | ||
| Pubmed | 1.89e-09 | 3 | 44 | 3 | 26770020 | ||
| Pubmed | Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability. | 6.60e-07 | 588 | 44 | 8 | 38580884 | |
| Pubmed | Ectomesenchymal Chondromyxoid Tumor: A Neoplasm Characterized by Recurrent RREB1-MKL2 Fusions. | 1.56e-06 | 2 | 44 | 2 | 29912715 | |
| Pubmed | 1.56e-06 | 2 | 44 | 2 | 11781319 | ||
| Pubmed | Structural basis of diverse membrane target recognitions by ankyrins. | 1.56e-06 | 2 | 44 | 2 | 25383926 | |
| Pubmed | 1.56e-06 | 2 | 44 | 2 | 23544943 | ||
| Pubmed | 1.56e-06 | 2 | 44 | 2 | 26673820 | ||
| Pubmed | N-Terminal Acetyltransferase Naa40p Whereabouts Put into N-Terminal Proteoform Perspective. | 2.13e-06 | 934 | 44 | 9 | 33916271 | |
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 20065027 | ||
| Pubmed | Human ankyrins and their contribution to disease biology: An update. | 4.69e-06 | 3 | 44 | 2 | 33410423 | |
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 35065708 | ||
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 23053434 | ||
| Pubmed | Shugoshin enables tension-generating attachment of kinetochores by loading Aurora to centromeres. | 4.69e-06 | 3 | 44 | 2 | 17322402 | |
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 35879412 | ||
| Pubmed | Regulation of membrane-associated mucins in the human corneal epithelial cells by dexamethasone. | 4.69e-06 | 3 | 44 | 2 | 17592322 | |
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 15611082 | ||
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 27483328 | ||
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 24204560 | ||
| Pubmed | Ankyrin-dependent Na+ channel clustering prevents neuromuscular synapse fatigue. | 4.69e-06 | 3 | 44 | 2 | 34289389 | |
| Pubmed | 4.69e-06 | 3 | 44 | 2 | 24939955 | ||
| Pubmed | Genomic convergence among ERRα, PROX1, and BMAL1 in the control of metabolic clock outputs. | 9.37e-06 | 4 | 44 | 2 | 21731503 | |
| Pubmed | TRPV4 activation in human corneal epithelial cells promotes membrane mucin production. | 9.37e-06 | 4 | 44 | 2 | 39024979 | |
| Pubmed | Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. | 9.37e-06 | 4 | 44 | 2 | 18198997 | |
| Pubmed | 1.13e-05 | 233 | 44 | 5 | 37704626 | ||
| Pubmed | 1.56e-05 | 5 | 44 | 2 | 25950943 | ||
| Pubmed | 1.56e-05 | 5 | 44 | 2 | 17058067 | ||
| Pubmed | Glial ankyrins facilitate paranodal axoglial junction assembly. | 1.56e-05 | 5 | 44 | 2 | 25362471 | |
| Pubmed | An ankyrin-based mechanism for functional organization of dystrophin and dystroglycan. | 1.56e-05 | 5 | 44 | 2 | 19109891 | |
| Pubmed | 1.56e-05 | 5 | 44 | 2 | 21346195 | ||
| Pubmed | 1.56e-05 | 5 | 44 | 2 | 18035521 | ||
| Pubmed | In vivo assembly of the axon initial segment in motor neurons. | 2.34e-05 | 6 | 44 | 2 | 23728480 | |
| Pubmed | 2.89e-05 | 1293 | 44 | 9 | 15342556 | ||
| Pubmed | Phosphorylation of the CPC by Cdk1 promotes chromosome bi-orientation. | 3.27e-05 | 7 | 44 | 2 | 20739936 | |
| Pubmed | Analysis of the role of membrane polarity in polycystic kidney disease of transgenic SBM mice. | 3.27e-05 | 7 | 44 | 2 | 7495297 | |
| Pubmed | 3.55e-05 | 146 | 44 | 4 | 29688375 | ||
| Pubmed | FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia. | 3.68e-05 | 497 | 44 | 6 | 36774506 | |
| Pubmed | 5.60e-05 | 9 | 44 | 2 | 20400778 | ||
| Pubmed | Potent and specific Atg8-targeting autophagy inhibitory peptides from giant ankyrins. | 5.60e-05 | 9 | 44 | 2 | 29867141 | |
| Pubmed | 6.39e-05 | 549 | 44 | 6 | 38280479 | ||
| Pubmed | Cell organization, growth, and neural and cardiac development require αII-spectrin. | 6.99e-05 | 10 | 44 | 2 | 22159418 | |
| Pubmed | 7.51e-05 | 177 | 44 | 4 | 26206133 | ||
| Pubmed | 8.55e-05 | 67 | 44 | 3 | 29254152 | ||
| Pubmed | Systematic analysis of human protein complexes identifies chromosome segregation proteins. | 8.84e-05 | 1155 | 44 | 8 | 20360068 | |
| Pubmed | 1.01e-04 | 191 | 44 | 4 | 20195357 | ||
| Pubmed | The in vivo Interaction Landscape of Histones H3.1 and H3.3. | 1.12e-04 | 608 | 44 | 6 | 36089195 | |
| Pubmed | Cooperative polarization of MCAM/CD146 and ERM family proteins in melanoma. | 1.12e-04 | 377 | 44 | 5 | 38117590 | |
| Pubmed | A census of human transcription factors: function, expression and evolution. | 1.33e-04 | 908 | 44 | 7 | 19274049 | |
| Pubmed | 1.41e-04 | 14 | 44 | 2 | 36213234 | ||
| Pubmed | 1.41e-04 | 14 | 44 | 2 | 21875947 | ||
| Pubmed | 1.54e-04 | 645 | 44 | 6 | 25281560 | ||
| Pubmed | Ankyrin-G regulated epithelial phenotype is required for mouse lens morphogenesis and growth. | 1.63e-04 | 15 | 44 | 2 | 30562487 | |
| Pubmed | 1.87e-04 | 421 | 44 | 5 | 36976175 | ||
| Pubmed | Transcriptomic landscape of early hair follicle and epidermal development. | 2.36e-04 | 18 | 44 | 2 | 37318953 | |
| Pubmed | 2.36e-04 | 18 | 44 | 2 | 37321992 | ||
| Pubmed | Ecm29-mediated proteasomal distribution modulates excitatory GABA responses in the developing brain. | 2.36e-04 | 18 | 44 | 2 | 31910261 | |
| Pubmed | 2.93e-04 | 20 | 44 | 2 | 33397958 | ||
| Pubmed | 3.06e-04 | 103 | 44 | 3 | 10574462 | ||
| Pubmed | 3.15e-04 | 104 | 44 | 3 | 9205841 | ||
| Pubmed | Identification of an FMNL2 Interactome by Quantitative Mass Spectrometry. | 3.33e-04 | 106 | 44 | 3 | 38891874 | |
| Pubmed | Large-scale characterization of HeLa cell nuclear phosphoproteins. | 4.09e-04 | 774 | 44 | 6 | 15302935 | |
| Pubmed | 4.18e-04 | 777 | 44 | 6 | 35844135 | ||
| Pubmed | E-cadherin is required for intestinal morphogenesis in the mouse. | 4.24e-04 | 24 | 44 | 2 | 22766025 | |
| Pubmed | 4.67e-04 | 119 | 44 | 3 | 23508102 | ||
| Pubmed | 6.89e-04 | 136 | 44 | 3 | 25429064 | ||
| Pubmed | E-cadherin interactome complexity and robustness resolved by quantitative proteomics. | 7.16e-04 | 565 | 44 | 5 | 25468996 | |
| Pubmed | Hepatocyte nuclear factor 4alpha is essential for embryonic development of the mouse colon. | 8.06e-04 | 33 | 44 | 2 | 16618389 | |
| Pubmed | Lhx2 is a direct NF-κB target gene that promotes primary hair follicle placode down-growth. | 8.06e-04 | 33 | 44 | 2 | 26952977 | |
| Pubmed | 1.24e-03 | 371 | 44 | 4 | 15747579 | ||
| Pubmed | An organelle-specific protein landscape identifies novel diseases and molecular mechanisms. | 1.26e-03 | 1321 | 44 | 7 | 27173435 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr7q22 | 1.23e-03 | 219 | 44 | 3 | chr7q22 | |
| Cytoband | 3q29 | 2.91e-03 | 83 | 44 | 2 | 3q29 | |
| Cytoband | 7q22.1 | 5.31e-03 | 113 | 44 | 2 | 7q22.1 | |
| GeneFamily | CD molecules|Mucins | 4.02e-10 | 21 | 35 | 5 | 648 | |
| Coexpression | GSE32423_CTRL_VS_IL7_MEMORY_CD8_TCELL_UP | 9.57e-07 | 198 | 44 | 6 | M5083 | |
| Coexpression | NABA_ECM_AFFILIATED | 9.58e-06 | 170 | 44 | 5 | M5880 | |
| Coexpression | GSE37301_LYMPHOID_PRIMED_MPP_VS_COMMON_LYMPHOID_PROGENITOR_UP | 2.10e-05 | 200 | 44 | 5 | M8853 | |
| Coexpression | TOMLINS_PROSTATE_CANCER_DN | 4.18e-05 | 40 | 44 | 3 | M11504 | |
| Coexpression | BURTON_ADIPOGENESIS_5 | 4.61e-05 | 118 | 44 | 4 | M1564 | |
| Coexpression | ALFANO_MYC_TARGETS | 4.91e-05 | 239 | 44 | 5 | M2477 | |
| Coexpression | BURTON_ADIPOGENESIS_5 | 4.92e-05 | 120 | 44 | 4 | MM1177 | |
| Coexpression | MURARO_PANCREAS_DELTA_CELL | 6.08e-05 | 250 | 44 | 5 | M39170 | |
| ToppCell | NS-critical-LOC-Epithelial|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.26e-08 | 199 | 44 | 6 | d64adb68502be596ce55fb2cb63fe1cfa2c5f8ba | |
| ToppCell | control-Epithelial|control / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls | 4.39e-08 | 200 | 44 | 6 | f95bbb94e51ac28b1995026c599ec3a34e012916 | |
| ToppCell | NS-moderate-d_0-4-Epithelial|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-08 | 200 | 44 | 6 | 64462a18afca3c1a8548a857924b8166058bf958 | |
| ToppCell | NS-control-d_0-4-Epithelial|d_0-4 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-08 | 200 | 44 | 6 | d014959891893b6d3854a471fba1dc50c6625a0a | |
| ToppCell | COVID-19-Epithelial_cells-Airway_club|COVID-19 / group, cell type (main and fine annotations) | 1.06e-06 | 185 | 44 | 5 | cfe6fd73d817e173fe803bc1683c291d9bcb8608 | |
| ToppCell | COVID-19-Epithelial_cells-Airway_goblet|COVID-19 / group, cell type (main and fine annotations) | 1.21e-06 | 190 | 44 | 5 | 51ca9ef4df3220487152fcf684147730637c7cc1 | |
| ToppCell | IPF-Epithelial-Club|World / Disease state, Lineage and Cell class | 1.24e-06 | 191 | 44 | 5 | 3c88a6f1d74bb3b9173cd0ea3a63c6d9570e3954 | |
| ToppCell | Bronchial-NucSeq-Epithelial-Epi_airway_secretory|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.38e-06 | 195 | 44 | 5 | e7230a849ea31e6eef9bc6f5468938499450582d | |
| ToppCell | NS-critical-d_07-13|critical / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.48e-06 | 198 | 44 | 5 | a6e11c87b31beffb6af190c64b4ef3ee1d9dab8d | |
| ToppCell | Bronchial-10x5prime-Epithelial|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.56e-06 | 200 | 44 | 5 | d3ee5f79513e2ac02ad3329b59e6290d457c44d2 | |
| ToppCell | Tracheal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.56e-06 | 200 | 44 | 5 | d3af0a706baf66e3f32e67b17dcfc31e5b32ce0e | |
| ToppCell | NS-control|NS / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 1.56e-06 | 200 | 44 | 5 | ecbe89ff95d046155b984c8c150e0b9e7278f839 | |
| ToppCell | Children_(3_yrs)-Epithelial-lung_goblet_cell-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor | 1.92e-05 | 161 | 44 | 4 | 2d63b279d9a5132e1c09b03930bf9039036d24a2 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_1/2_(AT1/AT2-like)|Adult / Lineage, Cell type, age group and donor | 2.01e-05 | 163 | 44 | 4 | e819a1d6d28290854aa0672b3a18fa9e293d8f23 | |
| ToppCell | PND03-Immune-Immune_Myeloid-DC-cDC2-cDC2_prolif|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 2.27e-05 | 168 | 44 | 4 | cc0dd43d5cda01e643d8e8d74ec7617d61890760 | |
| ToppCell | 3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.0.5|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.90e-05 | 179 | 44 | 4 | 6e965e424eebef50f0202cff75f458be395cfca1 | |
| ToppCell | nucseq-Epithelial-Epithelial_Glandular|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.90e-05 | 179 | 44 | 4 | 859cd8ee414ad6207c046ada2e655e49322dd01c | |
| ToppCell | ILEUM-non-inflamed-(7)_Lymphatics|non-inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 2.90e-05 | 179 | 44 | 4 | 99777a8931356d1206b8ab22aaa1b1d5a600b809 | |
| ToppCell | nucseq-Epithelial-Epithelial_Glandular-Goblet|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.97e-05 | 180 | 44 | 4 | 3dc80bc636bf0e6ffc9762853132a9fe59fd1f66 | |
| ToppCell | nucseq-Epithelial-Epithelial_Glandular-Goblet-Goblet|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.97e-05 | 180 | 44 | 4 | 668a2d8e1d5a390309d5eb62c836f5903144bea9 | |
| ToppCell | Control-Epithelial_cells-Airway_club|Control / group, cell type (main and fine annotations) | 3.03e-05 | 181 | 44 | 4 | c755d23dd9aabc717dc73e2b3fa99a1f751e6507 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.17e-05 | 183 | 44 | 4 | 6847c1252d6bb105524f812658112517fd351eab | |
| ToppCell | PND10-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_vascular-VSMC-VSMC_G2M|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 3.23e-05 | 184 | 44 | 4 | d1e0e3b0eed2db8a5b7e3d6f81294667e4ba64e5 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2/Club-like_(AT2/Club-like)|Adult / Lineage, Cell type, age group and donor | 3.30e-05 | 185 | 44 | 4 | 673f0c688ae6984bc8027df2da335787924f4137 | |
| ToppCell | ILEUM-inflamed-(7)_Lymphatics|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 3.30e-05 | 185 | 44 | 4 | d711dd2e91cfee723dae1ccb2b910b8cf3becc3b | |
| ToppCell | COPD-Epithelial-Goblet|World / Disease state, Lineage and Cell class | 3.37e-05 | 186 | 44 | 4 | d75fe7640a4b2c450c9759a1b3c3ef2a087f0092 | |
| ToppCell | Control-Epithelial-Club|World / Disease state, Lineage and Cell class | 3.37e-05 | 186 | 44 | 4 | 9798428691408e17ff2af2fe2d1b345f074d67e4 | |
| ToppCell | COPD-Epithelial-Club|World / Disease state, Lineage and Cell class | 3.37e-05 | 186 | 44 | 4 | 3006f4ab1eaf1eb34c10ca9f7c869603d2d25744 | |
| ToppCell | COVID-19-Epithelial-Ionocytes|COVID-19 / Condition, Lineage and Cell class | 3.52e-05 | 188 | 44 | 4 | a581cb9528d0febbf3addbb4f6bc140f91a584e6 | |
| ToppCell | COVID-19-Epithelial_cells|COVID-19 / group, cell type (main and fine annotations) | 3.52e-05 | 188 | 44 | 4 | c9cdee6f8d42ee69f5fb335f25084603c511bd29 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2-D231|Adult / Lineage, Cell type, age group and donor | 3.59e-05 | 189 | 44 | 4 | dab54a52358f66a8a9460cd6089a06c5fa7e7a5d | |
| ToppCell | IPF-Epithelial-Club|IPF / Disease state, Lineage and Cell class | 3.59e-05 | 189 | 44 | 4 | f3fcef008ef252b29ac6d567fef27f9acf9cd70f | |
| ToppCell | RV-15._Ventricular_Cardiomyocyte_III|World / Chamber and Cluster_Paper | 3.59e-05 | 189 | 44 | 4 | 0a82931b5f6c0a6427ca3edd5e2235ac49099d40 | |
| ToppCell | Control-Epithelial-ATII|Control / Disease state, Lineage and Cell class | 3.67e-05 | 190 | 44 | 4 | d50902a3abcc18aafa36d83cc2c6e07d7f7cb197 | |
| ToppCell | IPF-Epithelial-Goblet|IPF / Disease state, Lineage and Cell class | 3.67e-05 | 190 | 44 | 4 | e41dd5a997ad9952810ffecb57737c03ea1d88b3 | |
| ToppCell | IPF-Epithelial-Goblet|World / Disease state, Lineage and Cell class | 3.67e-05 | 190 | 44 | 4 | c29dabf0826663b9d6df51a7af9b76592090e44c | |
| ToppCell | 3'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 3.67e-05 | 190 | 44 | 4 | 2fdc024d3d673a0134b74b4c5a63afe924995730 | |
| ToppCell | COPD-Epithelial-Club|COPD / Disease state, Lineage and Cell class | 3.74e-05 | 191 | 44 | 4 | c909cf5fa0e6519aa93a47d2c3fcd2ae2163cd8d | |
| ToppCell | Children_(3_yrs)-Epithelial|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.74e-05 | 191 | 44 | 4 | e432c6e1ae82dddf84314ce73d2b7a991630d905 | |
| ToppCell | Children_(3_yrs)-Epithelial-alveolar_epithelial_cell_type_2|Children_(3_yrs) / Lineage, Cell type, age group and donor | 3.74e-05 | 191 | 44 | 4 | a0332a4ef629510fb313ec119195c44a3f704a80 | |
| ToppCell | Adult-Epithelial|Adult / Lineage, Cell type, age group and donor | 3.82e-05 | 192 | 44 | 4 | efb962a5fd3b9bdfd8cf8d13c435e29c8271713e | |
| ToppCell | Epithelial|World / Lineage, Cell type, age group and donor | 3.82e-05 | 192 | 44 | 4 | 499e8893afea5e6d3371e0bd018f7e86a524d669 | |
| ToppCell | COVID-19-lung-Secretory|COVID-19 / Disease (COVID-19 only), tissue and cell type | 3.82e-05 | 192 | 44 | 4 | 59261098ccb52306f837f632ebaea45b90ad30fe | |
| ToppCell | COPD-Epithelial|COPD / Disease state, Lineage and Cell class | 3.82e-05 | 192 | 44 | 4 | 0644fad5df18f0021f6f49cca996d8cf47f972ff | |
| ToppCell | COPD-Epithelial-Goblet|COPD / Disease state, Lineage and Cell class | 3.82e-05 | 192 | 44 | 4 | 93b2ca0a97776d28c7e8f1a0642c4b63a5554aab | |
| ToppCell | Control-Epithelial-Club|Control / Disease state, Lineage and Cell class | 3.82e-05 | 192 | 44 | 4 | d84ed1ea4a03edaa18c804f75afb03bd7b1f0e16 | |
| ToppCell | Epithelial-alveolar_epithelial_cell_type_2|World / Lineage, Cell type, age group and donor | 3.82e-05 | 192 | 44 | 4 | 58c3737be7acce39fd2b91d70d6d7b2bbaa4f710 | |
| ToppCell | Adult-Epithelial-alveolar_epithelial_cell_type_2|Adult / Lineage, Cell type, age group and donor | 3.90e-05 | 193 | 44 | 4 | 738f4f0a9ddde2432b429ab46838e353b1790589 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT2-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.90e-05 | 193 | 44 | 4 | fd4d3c0d7caf8a2fff5b3d901fc28d19a8163cdf | |
| ToppCell | 21-Trachea-Epithelial-Epithelial|Trachea / Age, Tissue, Lineage and Cell class | 3.90e-05 | 193 | 44 | 4 | 9a8bb44a37f3202e3123a6680bd5545dc91a6d40 | |
| ToppCell | nucseq-Epithelial-Epithelial_Alveolar-AT2|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 3.90e-05 | 193 | 44 | 4 | f3cc7cfdbc164a4ed42f87647111522b7d393bcb | |
| ToppCell | Parenchymal-10x5prime-Epithelial-Epi_airway_neuro-secretory|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.98e-05 | 194 | 44 | 4 | d024cd75a97f048257e49cee9190fb2e79202ee2 | |
| ToppCell | Parenchymal-10x5prime-Epithelial-Epi_airway_neuro-secretory-Ionocyte_n_Brush|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 3.98e-05 | 194 | 44 | 4 | ea5b7727ffef6cb454c501979a51bc1d4108d0e4 | |
| ToppCell | TCGA-Blood_and_Bone_Marrow-Primary_Tumor-Diffuse_large_B-cell_lymphoma-DLBCL-1|TCGA-Blood_and_Bone_Marrow / Sample_Type by Project: Shred V9 | 3.98e-05 | 194 | 44 | 4 | eaeeb84576270cc3fc59002ba33bff9639bb0b02 | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-endosteal_fibroblast|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 3.98e-05 | 194 | 44 | 4 | 69362e13158033de44f90f3773db6c0f27de8cb3 | |
| ToppCell | IPF-Multiplet-Multiplet|IPF / Disease state, Lineage and Cell class | 4.06e-05 | 195 | 44 | 4 | fce0c29574bb7aab181b9c00feb42681e285d1f2 | |
| ToppCell | Control-Multiplet|Control / Disease state, Lineage and Cell class | 4.06e-05 | 195 | 44 | 4 | 618900c80bea09d46dad3f741bd1bff8bf0a64ee | |
| ToppCell | IPF-Multiplet|IPF / Disease state, Lineage and Cell class | 4.06e-05 | 195 | 44 | 4 | eacc0449ae6f3ad8002268cd061467684c6fb9a7 | |
| ToppCell | Control-Multiplet-Multiplet|Control / Disease state, Lineage and Cell class | 4.06e-05 | 195 | 44 | 4 | 06ac685855e14e4dd2cbe6d0e73f894f2eeff91f | |
| ToppCell | IPF-Multiplet-Multiplet|World / Disease state, Lineage and Cell class | 4.06e-05 | 195 | 44 | 4 | 21dbdc803c6947024dc2416e9e21c2ef0af9bc31 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Epithelial-Epithelial,_Airway-ciliated_cell-Epi-Ciliated|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.14e-05 | 196 | 44 | 4 | 808c0a7d1889a8f3508ed9790c6dc7ec16bbc840 | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-transitional_Epi-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.14e-05 | 196 | 44 | 4 | 1efacc37bbfbd05b5d4db3dd10f6d9a238d23e31 | |
| ToppCell | COPD-Multiplet|COPD / Disease state, Lineage and Cell class | 4.14e-05 | 196 | 44 | 4 | 6d02d494196e3f857d53eea46d9419690d43beca | |
| ToppCell | COPD-Multiplet-Multiplet|COPD / Disease state, Lineage and Cell class | 4.14e-05 | 196 | 44 | 4 | af4cdc61830685a888a1209826c23bcf54a43084 | |
| ToppCell | IPF-Epithelial|IPF / Disease state, Lineage and Cell class | 4.14e-05 | 196 | 44 | 4 | 87d9881cfec461a5d89b688a83749b618c519485 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Epithelial-Epithelial,_Airway-ciliated_cell|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 4.14e-05 | 196 | 44 | 4 | b246e482f012dd9782b49c2a953acedfa3c1139d | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-transitional_Epi|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.14e-05 | 196 | 44 | 4 | 3e99a367b7d817e1f1221450fcec20ad7a7c7a2a | |
| ToppCell | Severe_COVID-19-Epithelial-transitional_Epi|Severe_COVID-19 / Disease group,lineage and cell class (2021.01.30) | 4.22e-05 | 197 | 44 | 4 | 5ad3cd4c77016e862041baac3076f8cc0f75c417 | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-transitional_Epi-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.22e-05 | 197 | 44 | 4 | 08b371309cd790b171ed76cabc7d910e71cd2835 | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.22e-05 | 197 | 44 | 4 | 5c4cee914baf7cb43e9cb99cc9e3ae823856dc15 | |
| ToppCell | 10x_3'_v3-tissue-resident_(10x_3'_v3)-myeloid-myeloid_monocytic-monocyte|tissue-resident_(10x_3'_v3) / Per Platform+tissue_group, by lineage_subgroup, cell_group, cell_type | 4.22e-05 | 197 | 44 | 4 | b2f4d7c301c0b24003374923b31d6d058e40b213 | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-transitional_Epi|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.22e-05 | 197 | 44 | 4 | 9f49feee38647bbf964974aac96fa75602186b5c | |
| ToppCell | 21-Trachea-Epithelial-Club-like_secretory|Trachea / Age, Tissue, Lineage and Cell class | 4.30e-05 | 198 | 44 | 4 | e735d82e5151c98b5724c543f8ad633c8ed824d2 | |
| ToppCell | BL-critical-LOC-Epithelial|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.30e-05 | 198 | 44 | 4 | 6218a25b94d5fa2c69880539adf9c63bfe52dcd3 | |
| ToppCell | Parenchymal-NucSeq-Epithelial-Epi_alveolar-AT2|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.30e-05 | 198 | 44 | 4 | 2e2a4e1756bba6f4fbe529559a97d2993c890b4b | |
| ToppCell | NS-critical-LOC-Epithelial-Secretory_LYPD2|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.30e-05 | 198 | 44 | 4 | 4a481e1edb80b950c823ed926842cd5132cfb27f | |
| ToppCell | 5'-Airway_Nasal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 4.30e-05 | 198 | 44 | 4 | d0ecace1fad24ce50b0935036fabb07e6c9e372d | |
| ToppCell | BAL-Mild-Epithelial-Epithelial|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.39e-05 | 199 | 44 | 4 | 1ee4010d8557564e25e8ee00b914c2dfd9037838 | |
| ToppCell | PSB-critical-LOC-Epithelial|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-05 | 199 | 44 | 4 | 58dcb0eedafa8629585dc99e53147e2287f49689 | |
| ToppCell | Bronchial-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.39e-05 | 199 | 44 | 4 | 5f7da3eab58ace6cddb3179a415cd839d5767958 | |
| ToppCell | NS-critical-d_07-13-Epithelial|d_07-13 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-05 | 199 | 44 | 4 | b88a81cd2a89f4d27100c96ae4324dcee68daf83 | |
| ToppCell | BAL-Mild-Epithelial-Epithelial|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.39e-05 | 199 | 44 | 4 | 1df69c0cb5f759f6a2152521842506a75bb95cae | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-Basal/Club|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.39e-05 | 199 | 44 | 4 | d04062d86643e5712cc2f519f4f36e643d404a16 | |
| ToppCell | Mild-Epithelial|Mild / Condition, Lineage, Cell class and cell subclass | 4.39e-05 | 199 | 44 | 4 | ec5fff80e2a8a94fbaf1fdcc6d45c8d7c6252e18 | |
| ToppCell | Mild-Epithelial-Epithelial-|Mild / Condition, Lineage, Cell class and cell subclass | 4.39e-05 | 199 | 44 | 4 | 81115bbd2c10bfdd38376d2075f03a59c31870d2 | |
| ToppCell | Parenchymal-NucSeq-Epithelial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 4.39e-05 | 199 | 44 | 4 | 5cea0d9e261903e0eaad60c28a07dff72ce65027 | |
| ToppCell | NS-critical-d_16-33-Epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-05 | 199 | 44 | 4 | 3b68197ec01c5f2b315d9e9b6eb02d5f6b5b77a3 | |
| ToppCell | Mild-Epithelial-Epithelial|Mild / Condition, Lineage, Cell class and cell subclass | 4.39e-05 | 199 | 44 | 4 | 91308b255783ad4029e5575028c18d7550832c51 | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-Basal/Club-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 4.39e-05 | 199 | 44 | 4 | a3f83fe5c3c557cd3ef8f5632f7fba5cf1859937 | |
| ToppCell | 5'-Adult-LargeIntestine-Endothelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.39e-05 | 199 | 44 | 4 | ffebd99d55d31cf51b4878b2690ed0b9b3799223 | |
| ToppCell | BAL-Mild-Epithelial|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.39e-05 | 199 | 44 | 4 | 74087b4b5e567310fc4ac58fb267ff651a180680 | |
| ToppCell | NS-moderate-d_16-33-Epithelial|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 4.39e-05 | 199 | 44 | 4 | aa2b51940115c22768c0d7493b4b60d41df3f376 | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-Basal/Club|Severe / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.39e-05 | 199 | 44 | 4 | 644197ff7e3299587881dd678836262e670ed4a8 | |
| ToppCell | Mild_COVID-19-Epithelial|Mild_COVID-19 / Disease group,lineage and cell class (2021.01.30) | 4.39e-05 | 199 | 44 | 4 | 72689bda7476930887ae007682fcab27f956f050 | |
| ToppCell | Severe_COVID-19-Epithelial-Basal/Club|Severe_COVID-19 / Disease group,lineage and cell class (2021.01.30) | 4.39e-05 | 199 | 44 | 4 | 2a0aebcfadff4e2dfc8244ad8a87c338ecccacfd | |
| ToppCell | BAL-Severe-Epithelial-Epithelial-Basal/Club-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 4.39e-05 | 199 | 44 | 4 | fd364f43859b2e7a3e91ce6a1c430cc42ad26a49 | |
| ToppCell | BAL-Mild-Epithelial|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 4.39e-05 | 199 | 44 | 4 | 00b5ce099c50a5e1786ce2b3a06ee0931a8205a4 | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_fibro-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 4.48e-05 | 200 | 44 | 4 | 747c61d4e0b746278ae1f45ca4cd556c6961c76a | |
| ToppCell | Parenchyma_Control_(B.)-Epithelial-TX-AT2-2|Parenchyma_Control_(B.) / Sample group, Lineage and Cell type | 4.48e-05 | 200 | 44 | 4 | 35c05cae30cd6b323d2662f1396ddeab08bc75fc | |
| ToppCell | LPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 4.48e-05 | 200 | 44 | 4 | 8988f113708eef7d9d2a6a6c1bcfd7c8f9804d3e | |
| Drug | Condelphine [7633-69-4]; Up 200; 8.8uM; HL60; HT_HG-U133A | 2.15e-06 | 198 | 44 | 6 | 2976_UP | |
| Drug | prochlorperazine dimaleate salt; Down 200; 10uM; MCF7; HT_HG-U133A_EA | 2.28e-06 | 200 | 44 | 6 | 995_DN | |
| Drug | Trichostatin A, from Streptomyces sp.; Down 200; 0.1uM; MCF7; HT_HG-U133A | 3.81e-05 | 197 | 44 | 5 | 3566_DN | |
| Drug | Neostigmine bromide [114-80-7]; Up 200; 13.2uM; MCF7; HT_HG-U133A | 3.81e-05 | 197 | 44 | 5 | 5335_UP | |
| Drug | Khellin [82-02-0]; Down 200; 15.4uM; MCF7; HT_HG-U133A | 3.81e-05 | 197 | 44 | 5 | 1504_DN | |
| Drug | Glimepiride [93479-97-1]; Up 200; 8.2uM; HL60; HT_HG-U133A | 3.90e-05 | 198 | 44 | 5 | 2154_UP | |
| Drug | Hydrastine hydrochloride [5936-28-7]; Up 200; 9.6uM; HL60; HG-U133A | 3.90e-05 | 198 | 44 | 5 | 1740_UP | |
| Disease | unipolar depression, neuroticism measurement | 5.35e-04 | 24 | 42 | 2 | EFO_0003761, EFO_0007660 | |
| Disease | plasminogen activator inhibitor 1 measurement | 2.70e-03 | 54 | 42 | 2 | EFO_0004792 | |
| Disease | insulin resistance | 3.21e-03 | 59 | 42 | 2 | EFO_0002614 | |
| Disease | response to opioid | 3.43e-03 | 61 | 42 | 2 | EFO_0008541 | |
| Disease | cutaneous melanoma, hair color | 3.54e-03 | 62 | 42 | 2 | EFO_0000389, EFO_0003924 | |
| Disease | cholangiocarcinoma (is_marker_for) | 3.77e-03 | 64 | 42 | 2 | DOID:4947 (is_marker_for) | |
| Disease | susceptibility to cold sores measurement | 3.89e-03 | 65 | 42 | 2 | EFO_0008402 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| PGESKTTSPSSPEED | 141 | Q9BT88 | |
| TDSASKPAEPTDVPT | 41 | A6H8Y1 | |
| EPSKSAESPTSPVTS | 276 | Q02952 | |
| PPSPDSKSDTTVESS | 3286 | Q8TCU4 | |
| LESPKESSEPTGSPA | 411 | P17544 | |
| PAISSPSPTTASKEG | 1046 | P58397 | |
| PGETSPPDSKSSPSV | 401 | Q9P0K7 | |
| DKSPSEESAPTTSPE | 121 | P54725 | |
| PSPSLSESSEDEKPT | 141 | Q9Y388 | |
| SGKSPLSPDTPSSEE | 2531 | Q01484 | |
| DTTPARTPTEEGTPT | 3081 | Q01484 | |
| HLPTGTTSPTKSPTE | 3261 | Q8WXI7 | |
| TDTPSASTGDTTPLP | 2516 | Q99102 | |
| DATTPSSVTSPTEGP | 411 | P40426 | |
| EPPDTTSPESPDTTS | 231 | Q13477 | |
| TSPESPDTTSPESPD | 236 | Q13477 | |
| PTSQGIPTSDEESTP | 206 | Q9NQS7 | |
| PTEGVKASSTSDPPA | 446 | Q8N307 | |
| SSPKESPSSTTPPIE | 291 | Q9HC44 | |
| EESEEPDSTTGTPPS | 1301 | O15054 | |
| GSAASPSEPKVSESP | 196 | Q9ULH7 | |
| SPSGSRPSTPKSDSE | 241 | Q14693 | |
| SSSDPSPSVSEETPG | 831 | A8MYU2 | |
| TSPSEKTTPSPTDKA | 581 | Q8TE49 | |
| PTPPLESSESSEGSK | 41 | Q13316 | |
| SSGKSPLTPETPSSE | 3161 | Q12955 | |
| PKSTTEPTPSPTTSE | 376 | P07359 | |
| KASSAPSPSSEPEEG | 156 | Q6XD76 | |
| PEATTSGKPEPVSSV | 121 | Q7Z2K8 | |
| EPASPDSPKGSSETE | 16 | P11474 | |
| DSPKGSSETETEPPV | 21 | P11474 | |
| TSTEASSPPPTAEGT | 1016 | Q685J3 | |
| TTSTEASSPPPTAEG | 2311 | Q685J3 | |
| EASTLSTPPGDTSTP | 3831 | Q685J3 | |
| ETEGSKPTKTPTTTP | 416 | Q5FBB7 | |
| SPPPVTTSSSKDEEE | 1111 | Q5T5P2 | |
| DGDTETSPTKSPTTP | 851 | Q13972 | |
| TTKGPTSTTSDKPAP | 806 | Q92954 | |
| SDPSSTPTKIPTDTS | 446 | O15516 | |
| TPPSQEDGKSPTTTL | 181 | O43829 | |
| SPKEETPGISSPETE | 36 | Q9H0M4 | |
| TSPKESSEPPAPASS | 1121 | Q92766 | |
| PKGTLSDTPTSSPTD | 906 | O95359 | |
| TTALGTTKESPPTSP | 156 | Q9P0L1 | |
| TTKESPPTSPLSGGS | 161 | Q9P0L1 | |
| TSTEPSTAKPSSPEP | 326 | Q96QC0 | |
| PEKPSESSAGPSTEE | 186 | Q13487 | |
| SKPTPTPEGTSQDVT | 171 | P53814 | |
| ETPSSSKTSPEPGQF | 421 | P51811 | |
| PGSPTTPSLSEKSTT | 2511 | Q9UKN1 |